Knight Therapeutics (TSE:GUD) Trading 1.6% Higher - Still a Buy?

Key Points

• Knight Therapeutics shares rose by 1.6% during trading, reaching a price of C$6.50, despite a significant decline in trading volume compared to averages.
• Analysts from Canaccord Genuity Group have set a price target of C$6.50 and rated the stock as a "buy," contributing to a consensus rating of "buy" with an average target price of C$7.15.
• The company reported a market capitalization of C$647.74 million and maintains a strong current ratio of 3.36, indicating a healthy liquidity position.

Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s stock price traded up 1.6% during trading on Monday . The stock traded as high as C$6.55 and last traded at C$6.50. 36,913 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 66,509 shares. The stock had previously closed at C$6.40.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group set a C$6.50 price target on Knight Therapeutics and gave the company a "buy" rating in a report on Friday, May 9th. One research analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to data from MarketBeat, Knight Therapeutics presently has a consensus rating of "Buy" and an average target price of C$7.15.

Knight Therapeutics Stock Up 1.6%

The company has a market capitalization of C$647.74 million, a PE ratio of -21.70, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.19. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. The firm has a 50-day moving average of C$6.18 and a two-hundred day moving average of C$5.96.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.